EC Number |
Inhibitors |
Structure |
---|
1.1.1.B40 | (3alpha,18beta,20beta)-3-methoxyamino-11-oxo-olean-12-en-29-oic acid |
- |
|
1.1.1.B40 | (3alpha,18beta,20beta)-3-methylsulfonylamino-11-oxo-olean-12-en-29-oic acid |
- |
|
1.1.1.B40 | (3beta)-3-(acetyloxy)-11-oxoolean-12-en-30-oic acid |
- |
|
1.1.1.B40 | (3beta)-3-hydroxy-11-oxoolean-12-en-30-amide |
- |
|
1.1.1.B40 | (3beta)-3-hydroxy-18,29-epoxyolean-12-ene-11,29-dione |
IC50 value for isoform 11beta-HSD2 above 25 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites |
|
1.1.1.B40 | (3beta)-3-hydroxyandrost-5-en-17-one |
treatment of rats induces a shift from isoform 11beta-HSD1 to 11beta-HSD2 expression, increasing conversion from active to inactive glucocorticoids. Dehydroepiandrosterone likely modulates the transcription of 11beta-HSD2 in a phosphatidylinositol-3 kinase/Akt-dependent manner by increasing CCAAT/enhancer-binding protein beta mRNA and protein expression |
|
1.1.1.B40 | (3beta)-3-[(3-carboxypropanoyl)oxy]urs-12-en-28-oic acid |
IC50 value for isoform 11beta-HSD2 above 3 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites |
|
1.1.1.B40 | (3beta)-30-[hydroxy(methyl)amino]-11,30-dioxoolean-12-en-3-yl acetate |
IC50 value for isoform 11beta-HSD1 above 1 microM. Docking studies into isoforms 11beta-HSD1 and 11beta-HSD2 binding sites |
|
1.1.1.B40 | (3beta)-N,3-dihydroxy-11-oxoolean-12-en-30-amide |
- |
|
1.1.1.B40 | (3beta,18beta,20beta)-11-oxo-3-succinylamino-olean-12-en-29-oic acid |
- |
|